Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rau

Showing results (161-170 of 167) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 167 results.
Cancers|September 28, 2023
Treatment of Colorectal Cancer in Certified Centers: Results of a Large German Registry Study Focusing on Long-Term SurvivalVinzenz Völkel, Michael Gerken, Kees Kleihues-van Tol, et al.
Clinical Pharmacology and Therapeutics|April 27, 2017
Population Pharmacokinetics of Liposomal Irinotecan in Patients With CancerB S Adiwijaya, J Kim, I Lang, et al.
Scientific Reports|January 22, 2025
Patient-derived xenografts from circulating cancer stem cells as a preclinical model for personalized pancreatic cancer researchBenedikt J Wagner, Andreas Ettner-Sitter, Nicolas A Ihlo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2017
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III TrialMarianne Sinn, Marcus Bahra, Torsten Liersch, et al.
Langenbeck'S Archives of Surgery|June 15, 2017
Survival outcome and prognostic factors after pancreatoduodenectomy for distal bile duct carcinoma: a retrospective multicenter studyEkaterina Petrova, Felix Rückert, Sebastian Zach, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2015
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancerJ S Chen, C Hsu, N J Chiang, et al.
Physical Review Letters|April 23, 2021
Dark Energy Survey Year 1 Results: Cosmological Constraints from Cluster Abundances, Weak Lensing, and Galaxy CorrelationsC To, E Krause, E Rozo, et al.
Pageof 17

Showing results (161-170 of 167) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 167 results.
Cancers|September 28, 2023
Treatment of Colorectal Cancer in Certified Centers: Results of a Large German Registry Study Focusing on Long-Term SurvivalVinzenz Völkel, Michael Gerken, Kees Kleihues-van Tol, et al.
Clinical Pharmacology and Therapeutics|April 27, 2017
Population Pharmacokinetics of Liposomal Irinotecan in Patients With CancerB S Adiwijaya, J Kim, I Lang, et al.
Scientific Reports|January 22, 2025
Patient-derived xenografts from circulating cancer stem cells as a preclinical model for personalized pancreatic cancer researchBenedikt J Wagner, Andreas Ettner-Sitter, Nicolas A Ihlo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2017
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III TrialMarianne Sinn, Marcus Bahra, Torsten Liersch, et al.
Langenbeck'S Archives of Surgery|June 15, 2017
Survival outcome and prognostic factors after pancreatoduodenectomy for distal bile duct carcinoma: a retrospective multicenter studyEkaterina Petrova, Felix Rückert, Sebastian Zach, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2015
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancerJ S Chen, C Hsu, N J Chiang, et al.
Physical Review Letters|April 23, 2021
Dark Energy Survey Year 1 Results: Cosmological Constraints from Cluster Abundances, Weak Lensing, and Galaxy CorrelationsC To, E Krause, E Rozo, et al.
Pageof 17